Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats

Journal of Virology

Volumn 79, Issue 21, 2005, Pages 13705-13713

  Shinozaki, Katsunori ^a   Ebert, Oliver ^a   Suriawinata, Arief ^a,b   Thung, Swan N ^a   Woo, Savio L C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; ONCOLYTIC VIRUS; VIRUS VECTOR;

ACUTE TOXICITY; ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IN VITRO STUDY; LETHALITY; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RNA VIRUS; TREATMENT INDICATION; TREATMENT OUTCOME; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; GENE THERAPY; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON TYPE I, RECOMBINANT; LIVER NEOPLASMS, EXPERIMENTAL; MALE; RATS; REASSORTANT VIRUSES; VESICULAR STOMATITIS-INDIANA VIRUS; VIRUS REPLICATION;

ANIMALIA; RNA VIRUSES; VESICULAR STOMATITIS VIRUS;

EID: 27144515258     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.21.13705-13713.2005     Document Type: Article

References (39)

1. Ahmed, M, M. O. McKenzie, S. Puckett, et al. 2003. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77:4646-4657.
2. Andersson, T., A. K. Mohammed, B. G. Henriksson, et al. 1993. Immunohistochemical and behaviour pharmacological analysis of rats inoculated intranasally with vesicular stomatitis virus. J Chem. Neuroanat. 6:7-18.
3. Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50:135-138.
4. Balachandran, S., M. Porosnicu, and G. N. Barber. 2001. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75:3474-3479.
5. Balachandran, S., and G. N. Barber. 2004. Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 5:51-65.
6. Belkowski, L. S., and G. C. Sen. 1987. Inhibition of vesicular stomatitis viral mRNA synthesis by interferons. J. Virol. 61:653-660.
7. Bray, M. 2001. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82:1365-1373.
8. Desforges, M., J. Charron, S. Berard, et al. 2001. Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res. 76:87-102.
9. Durbin, J. E., R. Hackenmiller, M. C. Simon, et al. 1996. Targeted disruption of the mouse Stall gene results in compromised innate immunity to viral disease. Cell 84:443-450.
10. Ebert, O., K. Shinozaki, T. G. Huang, et al. 2003. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:3605-3611.
11. Ebert, O., K. Shinozaki, C. Kournioti, et al. 2004. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64:3265-3270.
12. Fernandez, M., M. Porosnicu, D. Markovic, et al. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:895-904.
13. Ferran, M. C., and J. M. Lucas-Lenard. 1997. The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J. Virol. 71:371-377.
14. Francoeur, A. M., L. Poliquin, and C. P. Stanners. 1987. The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology 160:236-245.
15. Garcia-Sastre, A., R. K. Durbin, H. Zheng, et al. 1998. The role of interferon in influenza virus tissue tropism. J. Virol. 72:8550-8558.
16. Gobet, R., A. Cerny, E. Ruedi, et al. 1988. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp. Cell Biol. 56:175-180.
17. Huneycutt, B. S., Z. Bi, C. J. Aoki, et al. 1993. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J. Virol. 67:6698-6706.
18. Johnson, A. J., and J. T. Roehrig. 1999. New mouse model for dengue virus vaccine testing. J. Virol. 73:783-786.
19. Keskinen, P., M. Nyqvist, T. Sareneva, et al. 1999. Impaired antiviral response in human hepatoma cells. Virology 263:364-375.
20. Kirn, D., R. L. Martuza, and J. Zwiebel. 2001. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7:781-787.
21. Marcus, P. I., L. L. Rodriguez, and M. J. Sekellick. 1998. Interferon induction as a quasispecies marker of vesicular stomatitis virus populations. J. Virol. 72:542-549.
22. Melen, K., P. Keskinen, A. Lehtonen, et al. 2000. Interferon-induced gene expression and signaling in human hepatoma cell lines. J. Hepatol. 33:764-772.
23. Meraz, M. A., J. M. White, K. C. Sheehan, et al. 1996. Targeted disruption of the Stall gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431-442.
24. Miyoshi, K., D. H. Harter, and K. C. Hsu 1971. Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J. Neuropathol. Exp. Neurol. 30:266-277.
25. Mrkic, B., J. Pavlovic, T. Rulicke, et al. 1998. Measles virus spread and pathogenesis in genelically modified mice. J. Virol. 72:7420-7427.
26. Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:8843-8856.
27. Perrillo, R. P. 2004. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin. Liver Dis. 24:23-29.
28. Petersen, J. M., L. S. Her, V. Varvel, et al. 2000. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol. Cell. Biol. 20:8590-8601.
29. Reid, T., E. Galanis, J. Abbruzzese, et al. 2002. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62:6070-6079.
30. Richmond, J. Y., and S. L. Nesby-O'Dell. 2002. Laboratory security and emergency response guidance for laboratories working with select agents. Morb. Mortal. Wkly. Rep. Recomm. Rep. 51:1-6.
31. Rose, J. K., and M. A. Whitt. 2001. Rhabdoviridae: the viruses and their replicalion, p. 1221-1242. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
32. Ryman, K. D., W. B. Klimstra, K. B. Nguyen, et al. 2000. Alpha/beta interferon protects adult mice from fatal Sindbis virus infection and is an important determinant of cell and tissue tropism. J. Virol. 74:3366-3378.
33. Shinozaki, K., O. Ebert, C. Kournioti, et al. 2004. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol. Ther. 9:368-376.
34. Shinozaki, K., O. Ebert, and S. L. Woo. 2004. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41:196-203.
35. Stojdl, D. F., B. Lichty, S. Knowles, et al. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:821-825.
36. Stojdl, D. F., B. D. Lichty, B. R. tenOever, et al. 2003. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
37. van den Pol, A. N., K. P. Dalton, and J. K. Rose. 2002. Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J. Virol. 76:1309-1327.
38. von Kobbe, C., J. M. van Deursen, J. P. Rodrigues, et al. 2000. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell 6:1243-1252.
39. Yang, W. Q., X. Lun, C. A. Palmer, et al. 2004. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin. Cancer Res. 10:8561-8576.